Your browser doesn't support javascript.
loading
Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study.
Li, Yiqun; Tong, Zhongsheng; Wu, Xinhong; Ouyang, Quchang; Cai, Li; Li, Wei; Yu, Zhiyong; Han, Zhengxiang; Wang, Xiaojia; Li, Man; Wang, Haibo; Li, Li; Yang, Jin; Niu, Zhaofeng; Wang, Qitang; Xu, Binghe.
Afiliación
  • Li Y; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Tong Z; Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
  • Wu X; Department of Breast Surgery, Hubei Cancer Hospital, Wuhan, China.
  • Ouyang Q; Department of Breast Cancer Medical Oncology, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya Medical School, Central South University, Changsha, China.
  • Cai L; The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Li W; Department of Oncology, The First Hospital of Jilin University, Jilin, China.
  • Yu Z; Department of Breast Surgery, Shandong Cancer Hospital, Shandong Academy of Medical Science, Jinan, China.
  • Han Z; Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
  • Wang X; Department of Breast Medical Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital & Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
  • Li M; Department of Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
  • Wang H; Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
  • Li L; Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
  • Yang J; Departments of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
  • Niu Z; Department of Breast Center, Yuncheng Central Hospital, Yuncheng, China.
  • Wang Q; Breast Medical Center, Qingdao Central Hospital, Qingdao, China.
  • Xu B; National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Int J Cancer ; 153(10): 1809-1818, 2023 11 15.
Article en En | MEDLINE | ID: mdl-37543965
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Int J Cancer Año: 2023 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Int J Cancer Año: 2023 Tipo del documento: Article País de afiliación: China